BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
-10.66%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$551M
AUM Growth
–
Cap. Flow
+$551M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
31.05%
Holding
130
New
130
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Gilead Sciences
GILD
|
$21.4M |
| 2 |
CELG
Celgene Corp
CELG
|
$21.1M |
| 3 |
Medtronic
MDT
|
$20.7M |
| 4 |
Biogen
BIIB
|
$19.9M |
| 5 |
Abbott
ABT
|
$16M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 93% |
| 2 | Financials | 1.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Cooper Companies
COO
$13.4B
| $3.62M | 0.66% | +23,500 | New | +$3.62M |
|
|
IPXL
52
DELISTED
Impax Laboratories, Inc.
IPXL
| $3.46M | 0.63% | +108,000 | New | +$3.46M |
|
53
Pfizer
PFE
$141B
| $3.26M | 0.59% | +110,000 | New | +$3.26M |
|
|
ACHN
54
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $3.24M | 0.59% | +420,000 | New | +$3.24M |
|
55
Community Health Systems
CYH
$387M
| $3.24M | 0.59% | +174,840 | New | +$3.24M |
|
|
CERN
56
DELISTED
Cerner Corp
CERN
| $3.18M | 0.58% | +60,000 | New | +$3.18M |
|
57
Merck
MRK
$210B
| $3.18M | 0.58% | +60,000 | New | +$3.18M |
|
|
ARIA
58
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $3.16M | 0.57% | +495,000 | New | +$3.16M |
|
59
Masimo
MASI
$7.59B
| $3.14M | 0.57% | +75,000 | New | +$3.14M |
|
60
Halozyme
HALO
$8.56B
| $3.01M | 0.55% | +318,000 | New | +$3.01M |
|
|
NVDQ
61
DELISTED
Novadaq Technologies Inc.
NVDQ
| $2.99M | 0.54% | +270,000 | New | +$2.99M |
|
62
Nektar Therapeutics
NKTR
$568M
| $2.97M | 0.54% | +216,000 | New | +$2.97M |
|
|
VAR
63
DELISTED
Varian Medical Systems, Inc.
VAR
| $2.96M | 0.54% | +37,000 | New | +$2.96M |
|
64
Cencora
COR
$56.5B
| $2.94M | 0.53% | +34,000 | New | +$2.94M |
|
|
NUVA
65
DELISTED
NuVasive, Inc.
NUVA
| $2.92M | 0.53% | +60,000 | New | +$2.92M |
|
|
MDVN
66
DELISTED
MEDIVATION, INC.
MDVN
| $2.9M | 0.53% | +63,000 | New | +$2.9M |
|
67
Thermo Fisher Scientific
TMO
$186B
| $2.83M | 0.51% | +20,000 | New | +$2.83M |
|
68
Hologic
HOLX
$14.9B
| $2.8M | 0.51% | +81,000 | New | +$2.8M |
|
69
Neurocrine Biosciences
NBIX
$13.8B
| $2.57M | 0.47% | +65,000 | New | +$2.57M |
|
70
Eli Lilly
LLY
$657B
| $2.52M | 0.46% | +35,000 | New | +$2.52M |
|
|
SGEN
71
DELISTED
Seagen Inc. Common Stock
SGEN
| $2.39M | 0.43% | +68,000 | New | +$2.39M |
|
72
United Therapeutics
UTHR
$13.8B
| $2.33M | 0.42% | +19,300 | New | +$2.33M |
|
73
Inovio Pharmaceuticals
INO
$126M
| $2.31M | 0.42% | +265,000 | New | +$2.31M |
|
74
Alkermes
ALKS
$4.78B
| $2.24M | 0.41% | +65,500 | New | +$2.24M |
|
75
Agios Pharmaceuticals
AGIO
$2.19B
| $2.19M | 0.4% | +54,000 | New | +$2.19M |
|